ZBIO (Zenas BioPharma) Short-Term Debt: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZBIO Zenas BioPharma Inc ZBIO
8 GF Score
Price $32.32
! 4 Warning Signs
View Full Analysis

What is Zenas BioPharma Short-Term Debt?

Zenas BioPharma ZBIO +2.12% 8 Short-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates ZBIO with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Zenas BioPharma's Short-Term Debt for the quarter that ended in Jun. 2026 was $0.00 Mil.

Zenas BioPharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zenas BioPharma Short-Term Debt Related Terms

Zenas BioPharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma Short-Term Debt Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.00 0.00 0.00 0.00

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ZBIO
8GF Score
Zenas BioPharma Inc ZBIO
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Zenas BioPharma (ZBIO) has a Short-Term Debt of $0.00 Mil as of Jun. 2026.
Is Zenas BioPharma's Short-Term Debt too high?
Zenas BioPharma's current Short-Term Debt is $0.00 Mil. Overall, Zenas BioPharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's Short-Term Debt compare to ADMA and PGEN?
Zenas BioPharma's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Zenas BioPharma's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Zenas BioPharma's overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current Short-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
8GF Score

Get the complete analysis for ZBIO

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.32
Price